MXPA04001016A - Derivados de sulfonamida como inhibidores de la gamma secretasa. - Google Patents
Derivados de sulfonamida como inhibidores de la gamma secretasa.Info
- Publication number
- MXPA04001016A MXPA04001016A MXPA04001016A MXPA04001016A MXPA04001016A MX PA04001016 A MXPA04001016 A MX PA04001016A MX PA04001016 A MXPA04001016 A MX PA04001016A MX PA04001016 A MXPA04001016 A MX PA04001016A MX PA04001016 A MXPA04001016 A MX PA04001016A
- Authority
- MX
- Mexico
- Prior art keywords
- gamma secretase
- secretase inhibitors
- sulfonamide derivatives
- formula
- disclosed
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title abstract 3
- 239000003540 gamma secretase inhibitor Substances 0.000 title abstract 2
- 150000003456 sulfonamides Chemical class 0.000 title abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- -1 heteroaryl sulfonamides Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31006801P | 2001-08-03 | 2001-08-03 | |
| PCT/US2002/024293 WO2003013527A1 (en) | 2001-08-03 | 2002-08-01 | Sulfonamide derivatives as gamma secretase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04001016A true MXPA04001016A (es) | 2004-05-27 |
Family
ID=23200871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04001016A MXPA04001016A (es) | 2001-08-03 | 2002-08-01 | Derivados de sulfonamida como inhibidores de la gamma secretasa. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7122675B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1411944A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005504042A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1780621A (cg-RX-API-DMAC7.html) |
| AR (1) | AR035260A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2455861A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04001016A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003013527A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| EP1411944A1 (en) * | 2001-08-03 | 2004-04-28 | Schering Corporation | Sulfonamide derivatives as gamma secretase inhibitors |
| AU2002367147A1 (en) | 2001-12-27 | 2003-07-15 | Daiichi Pharmaceutical Co., Ltd. | Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS |
| GB0223039D0 (en) * | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0223038D0 (en) * | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| DE602004002567T2 (de) | 2003-02-17 | 2007-05-31 | F. Hoffmann-La Roche Ag | Piperidinbenzolsulfonamidderivate |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US7067509B2 (en) * | 2003-03-07 | 2006-06-27 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
| EP1640366A4 (en) | 2003-06-30 | 2009-05-13 | Daiichi Seiyaku Co | HETEROCYCLES METHYLSULFON DERIVATIVE |
| MXPA06001559A (es) | 2003-08-08 | 2006-05-15 | Schering Corp | Inhibidores de amina ciclica bace-1 que poseen una benzamida como sustituyente. |
| CA2534672A1 (en) | 2003-08-08 | 2005-02-17 | Schering Corporation | Cyclic amine bace-1 inhibitors having a heterocyclic substituent |
| CA2544350A1 (en) * | 2003-10-29 | 2005-05-12 | Elan Pharmaceuticals, Inc. | N-substituted benzene sulfonamides |
| JP2007526455A (ja) * | 2004-02-03 | 2007-09-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法 |
| EP2369014A1 (en) | 2004-02-03 | 2011-09-28 | The Regents Of The University Of Michigan Office Of Technology Transfer | Compositions and methods for characterizing, regulating, diagnosing and treating cancer |
| JP2007531742A (ja) * | 2004-04-05 | 2007-11-08 | シェーリング コーポレイション | 新規のγセクレターゼインヒビター |
| AU2005257904A1 (en) * | 2004-06-15 | 2006-01-05 | Merck Sharp & Dohme Corp. | Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease |
| EP1789404B1 (en) * | 2004-06-30 | 2010-03-24 | Schering Corporation | Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors |
| EP1781625B1 (en) | 2004-07-22 | 2010-12-15 | Schering Corporation | Substituted amide beta secretase inhibitors |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
| AU2006308847C1 (en) | 2005-10-31 | 2012-05-10 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| WO2007103114A2 (en) * | 2006-03-07 | 2007-09-13 | The Brigham & Women's Hospital, Inc. | Notch inhibition in the treatment or prevention of atherosclerosis |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| WO2007118854A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
| WO2007118853A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| US20100226922A1 (en) * | 2006-06-08 | 2010-09-09 | Dorothea Maetzel | Specific protease inhibitors and their use in cancer therapy |
| WO2008055924A1 (en) | 2006-11-07 | 2008-05-15 | Vib Vzw | Diagnosis and treatment of t-cell acute lymphoblastic leukemia |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| WO2008092002A2 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
| ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| EP1997805A1 (en) * | 2007-06-01 | 2008-12-03 | Commissariat à l'Energie Atomique | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans |
| WO2009040659A2 (en) | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| WO2009051661A2 (en) * | 2007-10-12 | 2009-04-23 | The Brigham And Women's Hospital, Inc. | Substituted aryl alkylamino-oxy-analogs and uses thereof |
| WO2011009064A1 (en) * | 2009-07-17 | 2011-01-20 | The J. David Gladstone Institutes | Methods of controlling cell proliferation |
| AU2010276215A1 (en) * | 2009-07-21 | 2012-02-16 | Auckland Uniservices Limited | Heteroaryl benzamides, compositions and methods of use |
| EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| EP2493497A4 (en) | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| WO2013059302A1 (en) | 2011-10-17 | 2013-04-25 | Nationwide Children's Hospital, Inc. | Products and methods for aortic abdominal aneurysm |
| WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
| WO2017023999A1 (en) * | 2015-08-03 | 2017-02-09 | Emory University | Methylsulfonamide derivatives and uses related thereto |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
| EP3823672A1 (en) | 2018-07-19 | 2021-05-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Combination for treating cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
| US5559128A (en) * | 1995-04-18 | 1996-09-24 | Merck & Co., Inc. | 3-substituted piperidines promote release of growth hormone |
| AU773273B2 (en) * | 1999-02-26 | 2004-05-20 | Bristol-Myers Squibb Company | Novel sulfonamide compounds and uses thereof |
| FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| CA2406652A1 (en) * | 2000-04-20 | 2001-11-01 | Nps Allelix Corp. | Aminopiperidines for use as glyt-1 inhibitors |
| HUP0303360A2 (hu) * | 2000-09-25 | 2004-01-28 | Actelion Pharmaceuticals Ltd. | Maláriaellenes hatású szubsztituált amino-aza-cikloalkánok és ezeket tartalmazó gyógyszerkészítmények |
| EP1411944A1 (en) * | 2001-08-03 | 2004-04-28 | Schering Corporation | Sulfonamide derivatives as gamma secretase inhibitors |
-
2002
- 2002-08-01 EP EP02761207A patent/EP1411944A1/en not_active Withdrawn
- 2002-08-01 JP JP2003518536A patent/JP2005504042A/ja active Pending
- 2002-08-01 CA CA002455861A patent/CA2455861A1/en not_active Abandoned
- 2002-08-01 US US10/210,803 patent/US7122675B2/en not_active Expired - Fee Related
- 2002-08-01 CN CNA028193520A patent/CN1780621A/zh active Pending
- 2002-08-01 AR ARP020102925A patent/AR035260A1/es unknown
- 2002-08-01 MX MXPA04001016A patent/MXPA04001016A/es unknown
- 2002-08-01 WO PCT/US2002/024293 patent/WO2003013527A1/en not_active Ceased
-
2005
- 2005-09-09 US US11/223,545 patent/US20060009467A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7122675B2 (en) | 2006-10-17 |
| WO2003013527A1 (en) | 2003-02-20 |
| US20060009467A1 (en) | 2006-01-12 |
| EP1411944A1 (en) | 2004-04-28 |
| CA2455861A1 (en) | 2003-02-20 |
| US20030216380A1 (en) | 2003-11-20 |
| CN1780621A (zh) | 2006-05-31 |
| AR035260A1 (es) | 2004-05-05 |
| JP2005504042A (ja) | 2005-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04001016A (es) | Derivados de sulfonamida como inhibidores de la gamma secretasa. | |
| NO992821L (no) | Ketobenzamider som calpain-inhibitorer | |
| ATE396988T1 (de) | Chinolin- und chianzolinderivate zur behandlung von tumoren | |
| MXPA05012268A (es) | N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa. | |
| EA200600509A1 (ru) | Соединения пиримидотиофена | |
| NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
| DE60328182D1 (de) | Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase | |
| DE60204452D1 (de) | Pyrazolo[1,5]pyridinderivate | |
| TW200602322A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
| NO20055714L (no) | Inhibitorer av fosfatidylinositol 3-kinase | |
| NO20062339L (no) | Hepatitt C virus-inhibitoerer | |
| DE60009511D1 (de) | Nematizide trifluorbutene | |
| MXPA05012837A (es) | Inhibidores de caspasa y usos de los mismos. | |
| ES2243579T3 (es) | Derivados de pirazolopirideno. | |
| CA2354774A1 (en) | Farnesyl protein transferase inhibitors | |
| EA200300982A1 (ru) | Гетероциклические производные для лечения рака и других пролиферативных заболеваний | |
| BR0209149A (pt) | Ftalazinonas | |
| NO20040881L (no) | Orale antidiabetes midler. | |
| NO20044526L (no) | Hemisterlinderivater og anvendelser derav | |
| MXPA03011954A (es) | Nuevos derivados de acido sulfonico. | |
| ATE482933T1 (de) | Sulfopyrrolderivate | |
| ATE513821T1 (de) | Thiadiazolin-derivate zur behandlung von krebs | |
| CY1109950T1 (el) | Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν | |
| DE69933885D1 (de) | Triphenylbutenderivate zur behandlung von neurologischen störungen | |
| MXPA04000036A (es) | Benzofuranos sustituidos con (hetero) arilo como ligandos 5-ht. |